Introduction
============

Euvolemia is a predictor of outcome in peritoneal dialysis (PD) patients [@B1], [@B2]. It is because volume overload is related with cardiac dysfunction [@B3], [@B4], arterial stiffness [@B5] and inflammation [@B6]. Although achievement of euvolemia is crucial in dialysis patients, assessment of volume status is relatively crude in clinical practice. Bioimpedance spectroscopy (BIS) measures conductance and reactance at different frequencies by measuring the flow of electrical current through the body, and allows accurate measurement of fluid status [@B7]. Different indices of hydration status are provided by the BIS, including extracellular water (ECW), intracellular water (ICW), total body water (TBW), and overhydration (OH). The ECW/TBW is most widely accepted as a hydration index, however it can be confounded by obesity [@B8], and it does not give the degree of tissue hydration. By contrast, the OH data provides an estimate of hydration in liters allowing the clinician to easily set a target weight for the patient without calculating an index [@B1]. Recently it was reported that the OH value was an independent predictor of death in PD patients [@B1].

Health-related quality of life (HRQOL) is a predictor of mortality in end-stage renal disease (ESRD) patients [@B9], [@B10]. Multiple factors are known to affect HRQOL in ESRD patients, including underlying disease, nutrition, inflammation, adverse effects of treatment modality, social support and rapport with care providers [@B10]-[@B14]. Recent literature showed that body composition is associated with HRQOL in hemodialysis patients [@B15]. It was also reported that hydration status is related with HRQOL in elderly dialysis patients, which included a relatively small number of patients [@B16]. However, whether the hydration status affects HRQOL has not been evaluated in a large number of dialysis patients in a prospective manner.

The Quality of Life of Dialysis (QOLD) study was designed to analyze the change in HRQOL, depressive symptoms, and body composition of dialysis patients in Korea. In this prospective, observational multi-center study, 708 PD patients were recruited from 24 centers in Korea. In the current analyses, we analyzed 481 PD patients who were eligible for both the hydration status and HRQOL data at baseline and after 12 months to examine the hypothesis that hypervolemia is associated with worse HRQOL in PD patients.

Methods
=======

Study population
----------------

We studied PD patients who participated in the QOLD study. The QOLD study is a prospective, observational multi-center study to analyze the change in HRQOL, depressive symptoms, and body composition of dialysis patients in Korea. Inclusion criteria were age ≥18 years and incident or prevalent dialysis patients. Exclusion criteria were those who had psychiatric disease, current malignancy or liver cirrhosis, who were bed-ridden, or who cannot undergo bioimpedance analysis because of defibrillators, artificial joints, pins or limb amputations. The study visits were conducted at each center at baseline and 12 months by study coordinators. At each visit (baseline and after 12 months), HRQOL, depressive symptoms, and body composition were assessed. Seven hundred eight PD patients were recruited from 24 centers in Korea.

In the current analyses, 481 PD patients, who were eligible for both the hydration status and HRQOL data at baseline and after 12 months, were included. As shown in Figure [1](#F1){ref-type="fig"}, 634 patients were eligible for the baseline OH value. We used the baseline OH value to classify the hydration status of the patients. The overhydration group (OH group) was defined according to a previous study which showed that 2.0 liters was a reasonable cutoff value for OH in PD patients (OH \>+2L) [@B17]. Normohydration group (NH group) was defined as patients with baseline OH value between ±2L (-2L≤ OH ≤+2L). Six patients who were in an underhydration status (OH \<-2L) were excluded from the current analysis as this study was to compare the OH group and NH group. Additionally, 111 patients who were lost for follow-up data, 33 patients who died during the study period and 3 patients who received renal transplantation were excluded. Among 481 patients included in this study, 266 patients were in the NH group and 215 patients were in the OH group at baseline.

The subjects were additionally stratified into quartiles according to the change in the OH value during 12 months. The change in the OH value was defined as the OH difference, which is the difference between the baseline OH value and that at 12 months (OH difference = OH value at baseline - OH value at 12 months). The OH difference quartiles were; quartile 1 (OH difference \<-1L, n = 120), quartile 2 (-1L≤ OH difference \<-0.1L, n = 120), quartile 3 (-0.1L≤ OH difference \<+1L, n = 121), and quartile 4 (OH difference ≥+1L, n = 120).

Instruments
-----------

HRQOL was examined using the Korean version of Kidney Disease Quality of Life-Short Form (KDQOL-SF) [@B18] at baseline and at 12 months. The KDQOL-SF includes 36 items derived from a generic, validated instrument (SF-36) as well as 43 kidney disease-targeted items and one overall health-rating item. This instrument has been validated in the ESRD population [@B19]. The SF-36 domain includes subscales of physical functioning, role-physical, bodily pain, general health, emotional well-being, role-emotional, social function, and vitality. The kidney disease-targeted items include subscales of symptom/problem list, effects of kidney disease, burden of kidney disease, work status, cognitive function, quality of social interaction, sexual function, sleep, social support, dialysis staff encouragement, and patient satisfaction to staff. Responses to the KDQOL-SF were used to determine the physical health component scores (PCS), mental health component scores (MCS), and kidney disease component scores (KDCS). The change in each component score of KDQOL-SF was defined as the HRQOL score difference, which is the difference between the baseline score and score at 12 months (PCS difference = PCS at baseline - PCS at 12 months; MCS difference = MCS at baseline - MCS at 12 months; KDCS difference = KDCS at baseline - KDCS at 12 months).

Measurements of hydration status and body composition
-----------------------------------------------------

The hydration status and body composition were assessed at baseline and after 12 months. The BIS device (Body Composition Monitor, Fresenius Medical Care, Germany) was used to measure bioimpedance at 50 frequencies between 5 and 1000 kHz. The measurement was performed by placing electrodes on one hand and one foot in the BIS device and entering current height and weight data into the machine. BIS measurements were performed with the peritoneal dialysate in situ, and were performed by one reference PD physician or nurse in each center. ECW, ICW, TBW, and OH were determined from the measured impedance data. The OH/ECW was calculated as the percentage of OH to ECW. The lean tissue index (LTI) was calculated as the quotient of lean tissue mass/height^2^ (kg/m^2^). The adipose tissue index (ATI) was calculated as the quotient of adipose tissue mass/height^2^ (kg/m^2^).

Other variables
---------------

Patients\' comorbid status was quantified using the modified Charlson Comorbidity Index (CCI) [@B20]. Blood pressure was recorded as the mean of two consecutive measurements with 5 minutes\' interval, using one single calibrated device in each center. Height and weight were measured using one single calibrated device in each center. Body mass index (BMI) was calculated as the quotient of weight/height^2^ (kg/m^2^). Peritoneal membrane characteristics were determined based on the results of the peritoneal equilibration test (PET) at the time of body composition measurements. Dialysis adequacy (total KT/Vurea per week), mean of renal urea and creatinine clearance (renal CrCl), 24-h urine volume, ratio of dialysate to serum creatinine at 4-h PET (D/P Cr), and laboratory values were collected. Dietary protein intake was estimated from the normalized protein equivalent of nitrogen appearance (nPNA) following the equation: PNA=15.1 + 0.1945 urea appearance (mM/24 h) + protein losses (g/24 h) [@B21].

Statistical analysis
--------------------

Continuous data are expressed as the mean ± standard deviation (SD) or the median (range). Categorical variables are expressed as percentage of total. The normality of the distribution was assessed by the Shapiro-Wilk test. Differences between the NH group and the OH group were determined using Student\'s t-test for variables with normal distribution or Wilcoxon rank-sum test for variables with non-normal distribution. Categorical variables were compared using a chi-square test or Fisher\'s exact test. Pearson\'s correlation analysis was used to determine the correlation between the OH difference and the HRQOL scores at 12 months. Analysis of covariance was used to compare differences in the HRQOL scores at 12 months between the OH difference quartiles. Linear regression test was used to determine the association of OH difference with the HRQOL scores at 12 months and the HRQOL score difference. Multivariate models included the significantly associated parameters according to their weight on univariate testing and clinically fundamental parameters. A *P* value of \< 0.05 was considered to indicate a statistically significant difference and statistical analysis was performed using SAS.

Ethics statement and trial registration
---------------------------------------

All participants gave written informed consent, and the study protocol was approved by the following institutional review boards of the centers participated in the study: Korea University Guro Hospital, Catholic University of Korea Bucheon St. Mary\'s Hospital, Incheon St. Mary\'s Hospital, St. Vincent\'s Hospital, St. Paul\'s Hospital, Uijeongbu St. Mary\'s Hospital, Daejeon St. Mary\'s Hospital and Seoul St. Mary\'s Hospital, Soonchunhyang University Hospital, Hallym University Medical Center, Hanyang University Medical Center, KyungHee University Medical Center, Veterans Health Service Medical Center, Daejeon Sun Hospital, Eulji University Hospital, Dankook University Hospital, Konyang University Hospital, Chungnam National University Hospital, Inje University Haeundae Paik Hospital, Wonju Severance Christian Hospital, Chosun University Hospital, Presbyterian Medical Center, St. Carollo Hospital, and Keimyung University Dongsan Medical Center. The study was conducted from August 2010 to May 2014.

The study was registered at clinicaltrials.gov (NCT01668628), and was conducted in adherence to the Declaration of Helsinki. The authors confirm that all onging and related trials for this intervention have been registered. There was a delay in registering this study because centers were additionally recruited to participate in this study.

Results
=======

Baseline characteristics
------------------------

Table [1](#T1){ref-type="table"} shows the baseline characteristics and laboratory and bioimpedance measurements of the total patients and the comparison between the NH group and OH group. More male, diabetes, and continuous ambulatory PD patients were in the OH group than the NH group. The OH group showed higher CCI, total drained dialysate volume, and systolic blood pressure compared to the NH group. The OH group had higher D/P Cr and more patients with high average or high membrane transporter types than the NH group. The OH group consisted of less patients using 1.5% glucose bags only and more patients using 2.5% glucose bag at least once a day. The nPNA values were significantly lower in the OH group compared to the NH group.

At baseline, the OH group showed lower haemoglobin and albumin levels than the NH group. As expected, the OH group showed higher TBW, ECW, ICW, OH, OH/ECW values than the NH group. The ATI was significantly lower in the OH group compared to the NH group, but there was no difference in the LTI.

HRQOL scores at baseline
------------------------

Each component score of KDQOL-SF at baseline was compared between the two groups. The average of PCS, MCS, and KDCS at baseline were significantly lower in the OH group compared with the NH group (NH vs. OH; PCS, 55.5 ± 16.2 vs. 51.5 ± 16.5, *P* = 0.008; MCS, 50.1 ± 10.6 vs. 47.5 ± 11.1, *P* = 0.009; KDCS, 69.3 ± 9.6 vs. 67.0 ± 9.6, *P* = 0.008; Fig [2](#F2){ref-type="fig"}).

The subscales of the KDQOL-SF at baseline were compared (Table [2](#T2){ref-type="table"}). Among the SF-36 domains, the OH group showed significantly lower scores in physical functioning, bodily pain, general health, and social function. Among the kidney disease-specific domains, the OH group showed significantly lower scores in effects of kidney disease, burden of kidney disease, and cognitive function.

Correlations between the OH difference and the HRQOL scores at 12 months
------------------------------------------------------------------------

Table [3](#T3){ref-type="table"} shows the correlation coefficients between the OH difference and subscales of the KDQOL-SF at 12 months. In unadjusted analysis, the OH difference showed positive correlations with scores of bodily pain and patient satisfaction. After adjustment for the baseline OH value, the OH difference showed significant positive correlations with scores of physical functioning, role-physical, bodily pain, general health, role-emotional, and social function in the SF-36 domains. In the kidney disease-specific domains, the OH difference showed significant positive correlations with scores of symptom problem list, effect of kidney disease, burden of kidney disease, cognitive function, sleep, social support and patient satisfaction after adjustment for the baseline OH value.

Impact of the OH difference on the HRQOL scores at 12 months
------------------------------------------------------------

Each component score of KDQOL-SF at 12 months was compared between the OH difference quartiles (Fig [3](#F3){ref-type="fig"}). As the OH difference quartile increased, there was a significant trend toward an increase in adjusted PCS, MCS, and KDCS at 12 months after adjustments for age, sex, dialysis vintage, diabetes, haemoglobin, albumin, CCI, total KT/Vurea per week, renal CrCl, nPNA, 24-h urine volume, the baseline OH value, and each baseline component score (PCS, *P* \< 0.001; MCS, *P* = 0.002; KDCS, *P* \< 0.001).

To evaluate whether the change in hydration status was associated with the HRQOL scores after 12 months, linear regression analysis was performed (Table [4](#T4){ref-type="table"}). After adjustments for age and sex (Model 1), the OH difference showed significant positive associations with PCS (*β* = 2.18, 95% confidence interval \[CI\] 1.27 - 3.09, *P* \< 0.001), MCS (*β* = 1.06, 95% CI 0.46 - 1.65, *P*\< 0.001), and KDCS (*β* = 1.05, 95% CI 0.54 - 1.56, *P* \< 0.001) at 12 months. These associations remained robust after adjustments for dialysis vintage, diabetes, haemoglobin, albumin, CCI, total KT/Vurea per week, renal CrCl, nPNA, 24-h urine volume and the baseline OH value (Model 2; PCS,*β* = 2.25, 95% CI 1.23 - 3.28, *P* \< 0.001; MCS, *β* = 1.08, 95% CI 0.40 - 1.77, *P* = 0.002; KDCS, *β* = 1.29, 95% CI 0.71 - 1.88, *P* \< 0.001). Moreover, these associations were significant after adjustments for baseline PCS, MCS, and KDCS, respectively (Model 3; PCS,*β* = 2.04, 95% CI 1.01 - 2.97, *P* \< 0.001; MCS, *β* = 1.02, 95% CI 0.38 - 1.65, *P* = 0.002; KDCS, *β* = 1.06, 95% CI 0.57 - 1.55, *P* \< 0.001).

Impact of the OH difference on the HRQOL score difference
---------------------------------------------------------

To evaluate whether the change in hydration status was associated with the change in HRQOL scores, linear regression analysis was performed (Table [5](#T5){ref-type="table"}). After adjustments for age and sex (Model 1), the OH difference was significantly negatively associated with the PCS difference (*β* = -1.64, 95% CI -2.47- -0.80, *P* \< 0.001), and the KDCS difference (*β* = -0.48, 95% CI -0.95 - -0.01, *P* = 0.04). These associations remained robust after adjustments for dialysis vintage, diabetes, haemoglobin, albumin, CCI, total KT/Vurea per week, renal CrCl, nPNA, 24-h urine volume and the baseline OH value (Model 2; PCS difference,*β* = -1.81, 95% CI -2.84 - -0.78, *P* \< 0.001; MCS difference, *β* = -0.92, 95% CI -1.65 - -0.20, *P* = 0.01; KDCS difference, *β* = -0.90, 95% CI -1.44 - -0.36, *P* = 0.001).

Discussion
==========

The QOLD study is the first multi-center study of change in HRQOL, depressive symptoms, and body composition in PD patients. The results of the present study show that the baseline hydration status was associated with the baseline HRQOL scores and that the change in hydration status was related with the HRQOL scores after 12 months and the change in HRQOL scores in PD patients. The associations were significant after adjusting multiple factors including nutrition, anemia, residual renal function, dialysis adequacy, as well as the baseline hydration status and baseline HRQOL scores. These findings implicate that interventions to achieve euvolemia may potentially improve the HRQOL in PD patients.

HRQOL is a powerful predictor of mortality in ESRD patients [@B9], [@B10]. Euvolemia is also a predictor of mortality in PD patients [@B1], [@B2]. However, monitoring of HRQOL is not routinely done and accurate assessment of volume status is relatively crude in clinical practice. The novelty of this study is that we demonstrated that the hydration status was associated with HRQOL, not only at baseline, but also after 12 months. At baseline, the OH group showed better baseline PCS, MCS, and KDCS compared to the NH group. We speculate several reasons for this association. First, the OH group was more anemic than the NH group. A previous systematic review demonstrated that hematocrit level showed a consistent relationship with HRQOL in ESRD patients [@B22]. Second, the OH group was more hypoalbuminemic than the NH group. Nutritional biomarkers including albumin are well known predictors of both generic and disease-specific HRQOL in ESRD patients [@B22]. Third, the OH group was more diabetic and had multimorbidity, both of which were shown to be negatively associated with HRQOL in ESRD patients [@B23]-[@B25]. After 12 months, the OH difference showed positive correlations with most of the subscales of the KDQOL-SF, after adjustment for the baseline OH value. This suggested that the decrease in hydration status (positive OH difference) was associated better HRQOL scores after 12 months. To strengthen the statistical power, we stratified the patients into quartiles according to the OH difference. The adjusted PCS, MCS, and KDCS after 12 months significantly increased as the OH difference quartiles increased. In regression analysis, the decrease in hydration status (positive OH difference) was independently associated with better PCS, MCS, KDCS after adjustments for multiple variables including the baseline OH value and baseline component score of KDQOL-SF. Moreover, the decrease in hydration status (positive OH difference) was independently associated with improvement in PCS, MCS, KDCS (negative PCS, MCS, and KDCS difference). These findings suggest that decrease in hydration status is associated with improvement in HRQOL score after 12 months. Interestingly, the OH difference was more strongly associated with PCS difference than it did with MCS difference or KDCS difference. As physical function is closely related with muscle mass and cardiac function, several mechanisms can be postulated. First, the increase in hydration status may reflect progressive muscle loss and malnutrition [@B26]. Second, the increase in hydration status may be related to cardiac injury. It was reported that there is a longitudinal correlation between ECW and brain natriuretic peptide [@B27], which is strongly related with cardiac abnormalities in PD patients [@B28].

Hypervolemia was a frequent finding in our patients. Among 481 patients included in this study, 44.7% of patients were overhydrated. This finding is similar to that from a multi-center European study of 639 PD patients, which showed that 53.4% of patients were overhydrated and 24% had OH values equivalent to \>2L [@B29]. In this study, all hydration indices were higher in the OH group than the NH group. The total drained dialysate volume was also higher and more patients used 2.5% glucose dialysates at least once in the OH group. However, the use of 4.25% glucose dialysate or icodextrin was not different. Although the OH group showed higher peritoneal transport characteristics, the proportion of automated PD was lower and the use of icodextrin was not different compared with the NH group. The reason for this is unclear, since it was a multi-center study. However, these findings suggest that the PD prescription or fluid and salt restriction failed to achieve euvolemia in our study population.

In this study, the OH group was more likely to be male, diabetic, and hypoalbuminemic and to have multiple comorbidities and higher blood pressures, which is consistent with previous reports [@B19]. The reason for the male predominance in the OH group is not clear, but a similar finding was shown in a study of non-dialysis dependent chronic kidney disease patients [@B30]. The relationship between hydration status and hypoalbuminemia was also reported previously [@B29], [@B31]. There may be several reasons. First, the low dietary protein intake may be involved, as the OH group demonstrated lower nPNA levels than the NH group. However, the LTI or the serum creatinine was not different between the two groups, suggesting that muscle mass was not different. Second, hypoalbuminemia *per se* determines tissue hydration. Radio labeled albumin used to determine plasma volume demonstrated that the excess fluid associated with hypoalbuminemia is due to extravascular rather than intravascular volume expansion, which results from reduced oncotic pressure [@B31]. Third, the hydration status can also be affected by peritoneal membrane transport characteristics [@B32]. Rapid peritoneal solute transport is associated with increased peritoneal protein losses, contributing to hypoalbuminemia [@B33]. Our study population showed higher D/P Cr and more high and high average transporters in the OH group, which supports the association between hydration status and hypoalbuminemia.

There are limitations to this study. First, the effects of medications which may affect the hydration status or anemia were not analyzed. Second, data of dietary fluid and salt intake were lacking. Whether the overhydrated patients had excessive sodium and water intake or the prescription of PD was inadequate cannot be determined in this study. Third, the direct effect of hydration status on HRQOL could not be proven due to the observational manner of this study. Fourth, subjects with loss of data were excluded from the analysis.

In conclusion, this study demonstrates that the hydration status negatively affects the HRQOL in PD patients. Interventions to control volume overload may improve the HRQOL in PD patients with better outcomes.

The authors want to thank Kyungdo Han (Department of Biostatistics, College of Medicine, The Catholic University of Korea) for his statistical analysis.
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![**The HRQOL scores at baseline according to the hydration status.**The average scores of PCS, MCS, and KDCS at baseline were significantly lower in the OH group compared with the NH group.](ijmsv13p0686g002){#F2}

![**The Adjusted HRQOL scores at 12 months according to the OH difference quartiles.**As the OH difference quartile increased, there was a significant trend toward an increase in scores of PCS (A), MCS (B), and KDCS (C) at 12 months. Adjustments were made for age, sex, dialysis vintage, diabetes, haemoglobin, albumin, CCI, total KT/Vurea, renal CrCl, nPNA, 24-h urine volume, the baseline OH value, and each component score at baseline (baseline PCS, MCS, and KDCS, respectively).](ijmsv13p0686g003){#F3}

###### 

Baseline characteristics and laboratory and bioimpedance measurements.

                                            Total patients in the current analysis   NH group          OH group          *P*
  ----------------------------------------- ---------------------------------------- ----------------- ----------------- ---------
  Age                                       51.3 ± 11.1                              50.9 ± 11.6       51.8 ± 10.4       0.38
  Male (%)                                  256 (53.2)                               117 (44)          139 (64.7)        \<0.001
  Dialysis vintage (mo)                     23.6 ± 34.1                              25.1 ± 34.7       21.6 ± 33.3       0.27
  Diabetes (%)                              208 (43.2)                               75 (28.2)         133 (61.9)        \<0.001
  Cause of ESRD (%)                                                                                                      \<0.001
  Diabetes                                  198 (41.2)                               67 (25.2)         131 (60.9)        
  Hypertension                              179 (37.2)                               124 (46.6)        55 (25.6)         
  Glomerulonephritis                        52 (10.8)                                37 (13.9)         15 (7)            
  Others                                    52 (10.8)                                38 (14.3)         14 (6.5)          
  CCI                                       2.6 ± 1.0                                2.4 ± 0.9         2.8 ± 1.1         \<0.001
  BMI (kg/m^2^)                             24.2 ± 3.5                               24.2 ± 3.7        24.2 ± 3.3        0.96
  Systolic blood pressure (mmHg)            132.2 ± 21.8                             128.8 ± 19.1      136.4 ± 24.2      \<0.001
  Diastolic blood pressure (mmHg)           80.7 ± 12.7                              79.7 ± 12.5       81.9 ± 12.9       0.05
  Peritoneal dialysis modality (%)                                                                                       \<0.001
  CAPD                                      424 (88.1)                               222 (83.5)        202 (94)          
  APD                                       57 (11.9)                                44 (16.5)         13 (6.1)          
  D/P Cr at 4-h PET                         0.60 ± 0.11                              0.59 ± 0.12       0.62 ± 0.11       0.005
  Type of membrane transport (%)                                                                                         0.007
  Low                                       82 (17.0)                                59 (22.2)         23 (10.7)         
  Low average                               232 (48.2)                               125 (47)          107 (49.8)        
  High average                              148 (30.8)                               72 (27.1)         76 (35.4)         
  High                                      19 (4.0)                                 10 (3.8)          9 (4.2)           
  Total drained dialysate volume (mL/day)   8469.3 ± 1328.0                          8336.0 ± 1370.4   8637.4 ± 1255.6   0.01
  Dialysate usage (%)                                                                                                    
  1.5% glucose bags only                    205 (42.6)                               126 (47.4)        79 (36.7)         0.02
  2.5% glucose bag at least once            253 (52.6)                               127 (47.7)        126 (58.6)        0.02
  4.25% glucose bag at least once           33 (6.9)                                 15 (5.6)          18 (8.4)          0.24
  Icodextrin bag usage                      18 (3.7)                                 9 (3.4)           9 (4.2)           0.64
  24-h urine volume (mL/day)                763.9 ± 555.5                            741.3 ± 540.6     793.6 ± 574.8     0.35
  Renal CrCl (mL/min/1.73m^2^)              3.55 (0, 163.4)                          3.6 (0, 163.4)    3.4(0, 74.3)      0.67
  Total KT/Vurea per week                   2.4 ± 1.1                                2.5 ± 1.1         2.3 ± 1.0         0.06
  nPNA (g/kg/day)                           0.58 ± 0.26                              0.6 ± 0.3         0.5 ± 0.2         0.003
  Laboratory measurements                                                                                                
  Haemoglobin (g/dL)                        10.7 ± 1.4                               10.8 ± 1.3        10.5 ± 1.4        0.003
  Creatinine (mg/dL)                        9.6 ± 3.7                                9.8 ± 3.7         9.4 ± 3.7         0.24
  Sodium (mEq/L)                            138.8 ± 3.4                              139 ± 3.4         138.6 ± 3.4       0.22
  Potassium (mEq/L)                         4.5 ± 1.6                                4.4 ±0.8          4.5 ± 2.2         0.53
  Albumin (g/dL)                            3.6 ± 0.5                                3.8 ± 0.4         3.4 ± 0.5         \<0.001
  Total cholesterol (g/dL)                  176.3 ± 42.6                             179.6 ± 42.0      172.1 ± 43.0      0.06
  C-reactive protein (g/dL)                 0.2 (0, 61.2)                            0.2 (0, 61.2)     0.2 (0, 18.8)     0.06
  Bioimpedance measurements                                                                                              
  TBW (L)                                   34.5 ± 7.1                               32.7 ± 6.8        36.7 ± 6.8        \<0.001
  ECW (L)                                   16.3 ± 3.5                               14.8 ± 2.8        18.2 ± 3.2        \<0.001
  ICW (L)                                   18.2 ± 4.1                               17.9 ± 4.1        18.5 ± 4          0.13
  OH (L)                                    2.2 ± 2.1                                0.8 (-1.8, 2)     3.5 (2.1, 9.6)    \<0.001
  OH/ECW (%)                                12.2 ± 10.7                              4.5 ± 6.2         21.7 ± 6.9        \<0.001
  LTI (kg/m2)                               14.4 ± 3.1                               14.3 ± 3.1        14.4 ± 3.1        0.86
  ATI (kg/m2)                               8.8 ± 4.1                                9.4 ± 4.3         8.1 ± 3.7         \<0.001

Values expressed with a plus/minus sign are the mean ± SD. Values expressed with a parentheses are the median (range).

NH group, normohydration group; OH group, overhydration group; ESRD, end-stage renal disease; CCI, Charlson comorbidity index; BMI, body mass index; CAPD, continuous ambulatory peritoneal dialysis; APD, automated peritoneal dialysis; D/P Cr at 4-h PET, the ratio of dialysate creatinine to plasma creatinine at 4-h peritoneal equilibration test; CrCl, creatinine clearance; nPNA, normalized protein equilvalent of nitrogen appearance; TBW, total body water; ECW, extracellular water; ICW, intracellular water; OH, overhydration; OH/ECW, the ratio of overhydration to extracellular water; LTI, lean tissue index; ATI, adipose tissue index.

###### 

Baseline HRQOL scores.

                                    Total patients (n = 481)   NH group (n = 266)   OH group (n = 215)   *P*
  --------------------------------- -------------------------- -------------------- -------------------- -------
  SF-36 domains                                                                                          
  Physical functioning              73.1 ± 22.4                75.3 ± 21.5          70.4±23.2            0.02
  Role-physical                     50 (0, 100)                50 (0, 100)          50(0,100)            0.33
  Bodily pain                       76.5 ± 22.9                79 ± 20.5            73.5±25.3            0.01
  General health                    39.9 ± 21.7                42.8 ± 21.1          36.4±22.1            0.001
  Emotional well-being              30.2 ± 14.8                29.7 ± 13.8          30.9±16              0.39
  Role-emotional                    74.5 ± 24.5                75.7 ± 22.5          73±26.8              0.25
  Social function                   69.6 ± 25.0                72.1 ± 24.5          66.5±25.2            0.01
  Vitality                          30.3 ± 14.3                30.2 ± 14.2          30.5±14.5            0.78
  Kidney disease-specific domains                                                                        
  Symptom problem list              79.2 ± 15.6                80.3 ± 14.7          77.8 ± 16.7          0.08
  Effect of kidney disease          75.6 ± 16.2                77.3 ± 16.1          73.5 ± 16.2          0.01
  Burden of kidney disease          36.4 ± 25.3                38.7 ± 25.9          33.5 ± 24.2          0.03
  Work status                       47.9 ± 25.3                47.6 ± 25            48.4 ± 25.8          0.73
  Cognitive function                83.5 ± 15.9                85.5 ± 14.6          81.1 ± 17.1          0.004
  Quality of social interaction     70.6 ± 14.4                71.0 ± 15.2          70 ± 13.3            0.45
  Sexual function                   65.0 ± 32.5                68.0 ± 32.4          61.2 ± 32.3          0.13
  Sleep                             69.3 ± 15.5                70.3 ± 15.6          68 ± 15.3            0.10
  Social support                    65.9 ± 23.6                66.7 ± 22.3          64.9 ± 25.2          0.41
  Dialysis staff encouragement      100 (0, 100)               100 (0, 100)         100 (0, 100)         0.81
  Patient satisfaction              66.7 ± 17.1                67.4 ± 21.8          65.8 ± 22.3          0.43

Values expressed with a plus/minus sign are the mean ± SD. Values expressed with a parentheses are the median (range).

NH group, normohydration group; OH group, overhydration group.

###### 

Correlations of the OH difference with the HRQOL scores at 12 months.

                                    Unadjusted*r*   *P*    Adjusted *r*^a^   *P*
  --------------------------------- --------------- ------ ----------------- ---------
  SF-36 domains                                                              
  Physical functioning              0.08            0.08   0.22              \<0.001
  Role-physical                     0.05            0.29   0.16              \<0.001
  Bodily pain                       0.10            0.02   0.18              \<0.001
  General health                    0.06            0.18   0.13              0.005
  Emotional well-being              0.08            0.10   0.02              0.61
  Role-emotional                    0.08            0.08   0.13              0.006
  Social function                   0.03            0.46   0.12              0.01
  Vitality                          0.02            0.62   0.009             0.84
  Kidney disease-specific domains                                            
  Symptom problem list              0.01            0.78   0.09              0.046
  Effect of kidney disease          0.05            0.30   0.15              0.001
  Burden of kidney disease          0.07            0.15   0.13              0.004
  Work status                       0.03            0.58   0.02              0.71
  Cognitive function                0.07            0.14   0.13              0.003
  Quality of social interaction0    0.008           0.85   0.03              0.51
  Sexual function                   -0.11           0.13   0.10              0.17
  Sleep                             0.07            0.15   0.12              0.007
  Social support                    0.08            0.08   0.12              0.009
  Dialysis staff encouragement      0.05            0.27   0.03              0.50
  Patient satisfaction              0.12            0.01   0.11              0.01

^a^Adjusted for the baseline OH value.

###### 

Regression coefficients of the OH difference for the HRQOL scores at 12 months.

                      β^a^   95% CI       *P*
  ------------------- ------ ------------ ---------
  PCS at 12 months                        
  Model 1             2.18   1.27, 3.09   \<0.001
  Model 2             2.25   1.23, 3.28   \<0.001
  Model 3             2.04   1.01, 2.97   \<0.001
  MCS at 12 months                        
  Model 1             1.06   0.46, 1.65   \<0.001
  Model 2             1.08   0.40, 1.77   0.002
  Model 3             1.02   0.38, 1.65   0.002
  KDCS at 12 months                       
  Model 1             1.05   0.54, 1.56   \<0.001
  Model 2             1.29   0.71, 1.88   \<0.001
  Model 3             1.06   0.57, 1.55   \<0.001

^a^Regression coefficient

Model 1: Adjusted for age and sex.

Model 2: Adjusted for Model 1 plus dialysis vintage, diabetes, haemoglobin, albumin, CCI, total KT/Vurea per week, renal CrCl, nPNA, 24-h urine volume and the baseline OH value.

Model 3: Adjusted for Model 2 plus baseline scores of PCS, MCS, and KDCS, respectively.

###### 

Regression coefficients of the OH difference for the HRQOL score difference.

                                                           β^a^    95% CI         *P*
  -------------------------------------------------------- ------- -------------- ---------
  PCS difference (PCS at baseline - PCS at 12 months)                             
  Model 1                                                  -1.64   -2.47, -0.80   \<0.001
  Model 2                                                  -1.81   -2.84, -0.78   \<0.001
  MCS difference (MCS at baseline - MCS at 12 months)                             
  Model 1                                                  -0.59   -1.19, 0.006   0.052
  Model 2                                                  -0.92   -1.65, -0.20   0.01
  KDCS difference (KDCS at baseline - KDCS at 12 months)                          
  Model 1                                                  -0.48   -0.95, -0.01   0.04
  Model 2                                                  -0.90   -1.44, -0.36   0.001

^a^Regression coefficient

Model 1: Adjusted for age and sex.

Model 2: Adjusted for Model 1 plus dialysis vintage, diabetes, haemoglobin, albumin, CCI, total KT/Vurea per week, renal CrCl, nPNA, 24-h urine volume and the baseline OH value.
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